CHRS: Pipeline advances and strong LOQTORZI sales position for growth, with major data readouts ahead
The conference highlighted a robust oncology pipeline focused on immune resistance, with LOQTORZI driving commercial growth and tagmokitug and casdozokitug advancing in multiple cancer indications. Key data readouts and new combination studies are expected by year-end and early next year.Based on C…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.